Abstract 408P
Background
Despite the recent progress of immune therapies and multi-kinase inhibitors such as Sora, the 5-year survival rate for late-stage HCC remains dismal. The high prevalence and distinct etiology of HCC in Asia Pacific represent high unmet medical needs. Considering EGFR and MET are frequently over-expressed in HCC and often correlate with poor prognosis, we evaluated the impact of Sora on EGFR and MET expression (expr) and TME in treating late-stage HCC. We also evaluated the association of EGFR and MET expr, etiology and TME.
Methods
Total 51 HCC patients (pts) with tumor tissues before 1st-line Sora treatment (Tx) and 43 paired post- Sora samples obtained for immunohistochemistry (IHC) and RNA sequencing (RNAseq) analysis. The formalin-fixed, paraffin-embedded (FFPE) tissues were analyzed for EGFR and MET expr by IHC using EGFR D38B1 and MET SP44 antibodies. Staining intensity was scored on a scale of 0, 1+, 2+ and 3+. RNAseq was successfully conducted in 60 FFPE tissues (33 pre- and 27 post- Sora samples) by TruSeq RNA Access library preparation. R package immunedeconv was used for TME estimation.
Results
The median duration of Sora Tx was 126 days for study group. Overall, H score of EGFR and MET expr was higher in post- Sora than in pre- Sora samples (Median value: EGFR 100 vs 55; MET 110 vs 85). On a pt level, increased EGFR and MET expr in IHC>=2+ was observed respectively in 53% and 41% of HCC pts post Sora Tx. Interestingly, H score of MET expr in HBV+ group was higher than that in HBV- group (p = 0.003). MET gene expr also showed similar trend (p = 0.002) but not for EGFR. Different cut-off for EGFR and MET IHC expr showed similar results as above. Furthermore, a trend of positive correlation was observed between robust MET IHC staining and myeloid dendritic cell activated score (RNAseq) post Sora Tx (n = 26).
Conclusions
This is the first time to report EGFR and MET IHC expr from pre- and post- Sora HCC samples using different cut off scores. EGFR and MET expr was higher in post- Sora than in pre- Sora samples. MET expr in HBV+ group was higher than that in HBV- group. The mechanisms and clinical significance of these observations warrant further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Janssen Research & Development.
Funding
Janssen Research & Development.
Disclosure
C.J. Yen: Non-Financial Interests, Institutional, Principal Investigator: National Cheng Kung University college of medicine- National Cheng Kung University Hospital. M. Qing, X. Lyu, M. Gormley, M. Xia: Financial Interests, Personal, Full or part-time Employment: Janssen Research & Development . J. Curtin, F. Yang, L. Zhou: Financial Interests, Institutional, Full or part-time Employment: Janssen Research & Development.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract